Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis.

Lancet
Stefan LeuchtJohn M Davis

Abstract

Relapse prevention with antipsychotic drugs compared with placebo in patients with schizophrenia has not been sufficiently addressed by previous systematic reviews. We aimed to assess the association between such drugs and various outcomes in patients with schizophrenia to resolve controversial issues. We searched the Cochrane Schizophrenia Group's specialised register for reports published before Nov 11, 2008; and PubMed, Embase, and ClinicalTrials.gov for those before June 8, 2011. We also contacted pharmaceutical companies and searched the reference lists of included studies and previous reviews. Randomised trials of patients with schizophrenia continued on or withdrawn from any antipsychotic drug regimen after stabilisation were eligible. Our primary outcome was relapse between 7 and 12 months. We also examined safety and various functional outcomes. We used the random effects model and verified results for the primary outcome with a fixed effects model. Heterogeneity was investigated with subgroup and meta-regression analyses. We identified 116 suitable reports from 65 trials, with data for 6493 patients. Antipsychotic drugs significantly reduced relapse rates at 1 year (drugs 27%vs placebo 64%; risk ratio [RR] 0·40, 95% C...Continue Reading

References

Dec 1, 1975·The American Journal of Psychiatry·J M Davis
Sep 11, 1990·The American Journal of Psychiatry·W T CarpenterR W Buchanan
Feb 1, 1986·The British Journal of Psychiatry : the Journal of Mental Science·T J CrowE C Johnstone
Sep 1, 1986·Controlled Clinical Trials·R DerSimonian, N Laird
Jan 1, 1973·Archives of General Psychiatry·G E Hogarty, S C Goldberg
Sep 11, 1971·British Medical Journal·J P Leff, J K Wing
Jun 1, 1981·The British Journal of Psychiatry : the Journal of Mental Science·H K Cheung
Jan 1, 1982·Psychopharmacology·T NishikawaY Uchida
May 1, 1994·Drugs·J M DavisL ] Metalon L [corrected to Matalon
Mar 1, 1995·Archives of General Psychiatry·R J Baldessarini, A C Viguera
Jan 1, 1997·Archives of General Psychiatry·A C VigueraM Tohen
Nov 7, 1998·BMJ : British Medical Journal·D G Altman
Sep 6, 2003·BMJ : British Medical Journal·Julian P T HigginsDouglas G Altman
Apr 1, 1964·Journal of Chronic Diseases·E M CAFFEYC ROTHSTEIN
Nov 19, 2003·Journal of Clinical Psychopharmacology·Charles M BeasleyUNKNOWN Olanzapine Relapse Prevention Study Group
Nov 25, 2003·The Journal of Clinical Psychiatry·Teresa A PigottUNKNOWN Aripiprazole Study Group
Jun 10, 2008·Journal of Clinical Epidemiology·Jaime L PetersLesley Rushton
May 15, 2009·The New England Journal of Medicine·Ross J Baldessarini
Apr 3, 2010·The American Journal of Psychiatry·David M GardnerRoss J Baldessarini
Mar 3, 2011·The American Journal of Psychiatry·Jari TiihonenPasi Korhonen
Nov 30, 2011·International Journal of Psychiatry in Clinical Practice·Geartsje BoonstraRené S Kahn

❮ Previous
Next ❯

Citations

Apr 2, 2013·Archives of Pharmacal Research·Eun Ji ParkDong Hee Na
Mar 21, 2013·Schizophrenia Bulletin·Martin Harrow, Thomas H Jobe
Jan 24, 2013·Therapeutic Advances in Chronic Disease·Erik Johnsen, Rune A Kroken
Oct 17, 2013·Indian Journal of Pharmacology·Siddharth Sarkar, Sandeep Grover
Nov 19, 2013·Schizophrenia Research·A B P StaringC L Mulder
Jan 31, 2014·Evidence-based Mental Health·John M Kane
Oct 3, 2014·The British Journal of Psychiatry : the Journal of Mental Science·Ross White, S P Sashidharan
Sep 14, 2014·Asian Journal of Psychiatry·Dawn BruijnzeelRajiv Tandon
Sep 13, 2014·European Archives of Psychiatry and Clinical Neuroscience·Mathias ZinkAndrea Schmitt
Feb 12, 2013·BMC Psychiatry·Robin EmsleyBrian H Harvey
Jul 28, 2013·The British Journal of Psychiatry : the Journal of Mental Science·Thomas R E BarnesShôn W Lewis
Aug 15, 2012·Molecular Psychiatry·W T Carpenter, J M Davis
Feb 13, 2016·Expert Opinion on Pharmacotherapy·Steven G Potkin, Adrian Preda
Feb 18, 2016·Schizophrenia Research·Jessica DaganiGiovanni de Girolamo
Feb 9, 2016·Diagnostics·Amer M BurhanFrank S Prato
Sep 25, 2012·Lancet·Andrea MessoriSabrina Trippoli
May 9, 2012·Lancet·Jim van Os, Oliver D Howes
Feb 28, 2015·Journal of Psychiatric and Mental Health Nursing·R Gray
Mar 25, 2016·Behavioral Sciences & the Law·James B Reynolds
Feb 13, 2015·Journal of Mental Health·Harpal Singh Nandhra, Akeem Sule
Nov 26, 2015·Pharmacotherapy·Stacy L HaberDavid Alexander Sclar
Jun 15, 2013·Expert Review of Pharmacoeconomics & Outcomes Research·Laurent BoyerPascal Auquier
Feb 5, 2014·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Maxine X PatelStephen J Cooper
Sep 28, 2015·Social Psychiatry and Psychiatric Epidemiology·Lone Baandrup, Marie Kruse
Sep 26, 2015·Early Intervention in Psychiatry·Georgia L StevensJacqueline Zummo
Jul 25, 2014·Human Psychopharmacology·Takefumi SuzukiMasaru Mimura

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here